All Oncology News

Thomas E. Hutson, DO, PharmD, discusses how nivolumab, cabozantinib, and lenvatinib/everolimus have significantly impacted the management of patients with renal cell carcinoma and promising combination regimens on the horizon to propel the field forward.

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

In metastatic castration-resistant prostate cancer, pain and hemoglobin levels, PSA levels, and ECOG performance status may predict which patients will be able to receive the recommended 6-dose regimen of radium-223 dichloride (Xofigo).

Amid growing evidence of their importance in the immune system, myeloid-derived suppressor cells are gaining traction as a target for anticancer therapies.

Richard G. Stock, MD, discusses the ideal patient for radium-223 dichloride (Xofigo), its proper sequencing with metastatic castration-resistant prostate cancer, and the future outlook for the therapy.

The United States Preventative Services Task Force recommends screening for colorectal cancer using traditional colonoscopy or one of 7 tests at various frequencies for all patients aged 50 to 75.

Noah Federman, MD, discusses challenges with treating pediatric patients and adolescent and young adults with sarcomas and ongoing efforts to overcome these obstacles.

NICE has approved the combination of nivolumab and ipilimumab for patients with metastatic melanoma, which allows the combination to be used within NHS.

Rolling submission of a new drug application for brigatinib (AP26113) has been initiated for patients with advanced ALK-positive non–small cell lung cancer who are resistant to prior crizotinib (Xalkori).

Brian A. Van Tine, MD, PhD, discusses ongoing research in sarcomas, as well as provides insight on the impact existing drugs are making on the treatment landscape and what community oncologists need to know about this ever-changing field.

Jonathan C. Trent, MD, PhD, discusses notable findings in sarcomas that emerged at the 2016 ASCO Annual Meeting, as well as what lies ahead for the field of sarcomas.

Frontline pembrolizumab (Keytruda) improved overall survival versus chemotherapy in non–small cell lung cancer patients with high levels of PD-L1 expression.

Single-agent duvelisib demonstrated an overall response rate of 46% for patients with indolent non-Hodgkin lymphoma, which successfully met the primary endpoint for the phase II DYNAMO study but not investor expectations.

The European Commission approved obinutuzumab (Gazyvaro, EU; Gazyva, US) for use in combination with bendamustine, followed by maintenance obinutuzumab, as a treatment for patients with follicular lymphoma who are refractory to or progress on a single-agent rituximab (MabThera) or rituximab-containing regimen.

In patients with advanced colorectal cancer, the combination regimen of cobimetinib (Cotellic) and atezolizumab (Tecentriq) was found to demonstrate clinical activity as well as have a good safety profile.

David F. McDermott, MD, provides further insight on the long-term efficacy and safety of nivolumab and its role in renal cell carcinoma, as well as potential combination regimens and challenges with sequencing nivolumab.

Phase I findings of a study examining the efficacy of osimertinib (Tagrisso) in heavily pretreated patients with EGFR-mutated advanced non-small cell lung cancer and leptomeningeal disease showed promising activity in the patient population.

The L'Oreal Paris USA-MRA Team Science Award for Women in Scientific Research grant for $900,000 is focused on understanding and treating metastatic melanoma.

The program brings both high-school and undergraduate students from underrepresented populations to the IU School of Medicine's Indianapolis campus. It offers students positive and meaningful firsthand exposure to biomedical and behavioral science careers that might not otherwise present themselves.

A combination regimen involving abiraterone acetate (Zytiga) and low-dose prednisone demonstrated a median time to radiographic progression of 41.4 months, as well as a median time to prostate-specific antigen progression of 28.7 months, in men with nonmetastatic castration-resistant prostate cancer.

The combination of the oncolytic virus talimogene laherparepvec (T-VEC) and pembrolizumab (Keytruda) demonstrated evidence of clinical benefit, as well as an acceptable safety profile, in patients with advanced melanoma.

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.

Pembrolizumab demonstrated an objective response rate of 18% in data from two clinical trials exploring the PD-1 inhibitor as a treatment for patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma.

Keith T. Flaherty, MD, discusses choosing between immunotherapy and targeted therapy in the frontline setting for patients with BRAF-mutated melanoma.

In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib (Lynparza) was found to significantly increase overall survival when given as maintenance therapy.

Results of an analysis presented at the 2016 ASCO Annual Meeting demonstrate the difficulty in determining the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer (CRC) who do not harbor Lynch syndrome.

A device using tumor treating fields that was administered to patients with unresectable pancreatic cancer showed early signs of tolerability and safety when in combination with gemcitabine in the frontline setting.

The European Commission approved bevacizumab in combination with erlotinib as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent EGFR-mutant non–small cell lung cancer.

Sacituzumab govitecan (IMMU-132) had an objective response rate of 33% in pretreated patients with triple-negative breast cancer, according to updated findings from a phase II study reported by Immunomedics, the manufacturer of the antibody-drug conjugate.

OncLive, a leading provider of news, resources and information to oncology professionals, today announced that an elite panel of oncology specialists has chosen finalists for the 2016 Giants of Cancer Care Awards, which recognize and celebrate pioneers, innovators and future generations of leaders for their remarkable achievements in oncology research and clinical practice.